Tonisity Launches Tonisity PxM® – Its Third Generation Solution For Swine Producers
Tonisity PxM - Isotonic Milk Replacer Additive Helps Piglets Overcome Key Productivity Hurdles

Tonisity Launches Tonisity PxM® – Its Third Generation Solution For Swine Producers

Isotonic Milk Replacer Additive Helps Piglets Overcome Key Productivity Hurdles

Dublin, Ireland (November 21, 2022) – Tonisity International Limited (“Tonisity”), an animal health and nutrition company based in Ireland, is pleased to announce that it has launched Tonisity PxM (PxM) – an isotonic milk replacer additive that helps piglets overcome key productivity hurdles. PxM is Tonisity’s third product of its unique isotonic drink range for the enhancement of swine production.

About Tonisity PxM

Tonisity PxM is a bioactive pack specifically formulated to be mixed with milk replacers, which are widely used in farrowing houses to supplement the sows’ milk. PxM includes Tonisity’s gut-enhancing bioactives in a milk replacer compatible formula and will be highly complementary to Tonisity’s existing swine products, Tonisity Px® and Tonisity PxW®, which are focused on the farrowing and weaning stages of the lives of piglets.

Tonisity PxM 5kg and 1kg Pack

Administering PxM on farms is very straightforward – as it is simply mixed with milk replacers in existing delivery systems on the farms. Tonisity PxM is flexible since it is designed to match the milk replacer administration schedule of the farm. Only 0.5% of PxM is required to be added to the liquid milk replacer.

In a recent trial at a 400-sow farm in Eastern Europe, Tonisity PxM was administered over a period of 17 days and resulted in a 51% reduction in pre-weaning mortality, with +36 extra piglets gained per 1,000 born.[1] Further, the pigs gained 220 grams of extra weaning weight[2], giving the farm an 11:1 return on investment.

Tonisity PxM was launched at the EuroTier trade fair in Hanover, Germany on November 15th. EuroTier is the leading international trade fair for professional animal farming and livestock management. Tonisity is expecting to begin selling Tonisity PxM to its customers that use milk replacers in December 2022.

Mathieu Cortyl, Managing Director for Tonisity International, comments,
“With the ongoing challenges of pig production worldwide, it is clear that litters need additional nutrition. Tonisity PxM is an innovative solution that is easy to use, results in important production gains and will produce significant returns on investment for customers.
We are proud to be adding another cutting-edge product to our suite of isotonic swine products.”

Mihai Condu, manager at the Agromar farm in Romania, and who conducted the PxM evaluation, comments,
“We were delighted to hear about Tonisity PxM and asked to test it immediately. We simply mixed it in the milk replacer, and the well-known benefits of Tonisity’s bioactives were quick to appear. The piglets drank the milk replacer better and were more active. Pre-weaning mortality halved, and we weaned heavier, more uniform pigs. With Tonisity PxM, we are able to provide additional support to the intestine of these young piglets. As a result, we have more, better quality and healthier pigs for sale.
This is the biggest improvement our team has ever seen.”

Tonisity’s suite of gut-enhancing products improve pigs’ survival, especially during their first month of life, in which up to 15% of piglets die mainly due to a lack of nutrition and gut health issues. The increased survivability of piglets, together with better performance pre- and post-weaning, enables producers to sell their pigs into the market with return of investments that can reach 5-10x. These benefits are especially important in an age of African swine fever and increased labour and feed cost inputs.

For More Information on Tonisity

Tonisity is an animal health and nutrition company based in Ireland that is currently focusing its patented technology in two specific markets: (1) isotonic products for the enhancement of swine production; and (2) novel companion animal nutrition products. Tonisity is focused on creating positive physiological changes by addressing the issue of intestinal health of young animals, thus improving their overall health, leading to better lifetime performance. With respect to novel companion animal products, Tonisity is poised to become the first mover and market leader in a targeted nutrition approach for pets – which is a rapidly growing market across the globe. For more information on Tonisity’s isotonic business, visit For more information on Tonisity’s companion animal business, visit


“Arie Halpern”

Arie Halpern
CEO and Chairman

Forward-Looking Statements

This press release contains forward-looking statements and information that are based on the beliefs of management and reflect Tonisity’s current expectations. When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information.

The forward-looking statements and information in this press release include information relating to the business plans of Tonisity, including the development of new product lines in both the swine and companion animal product lines.

Such statements and information reflect the current views of Tonisity. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: Tonisity’s ability to raise capital to maintain its growth and business objectives, Tonisity’s ability to negotiate and enter into binding agreements with counterparties in geographic markets that are part of its expansion plans, changes in laws and regulations that could adversely affect Tonisity’s business, growth or results of operations, Tonisity’s ability to attract and retain customers and consumers and impacts of the COVID-19 pandemic.

There are a number of important factors that could cause Tonisity’s actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others: limited business history of Tonisity; risks related to Tonisity’s corporate strategy including that previous and future acquisitions do not meet expectations; disruptions or changes in the credit or security markets; results of operation activities; unanticipated costs and expenses, fluctuations in commodity prices, and general market and industry conditions; protection of Tonisity’s intellectual property; disruption at any of Tonisity’s facilities including as a result of the current COVID-19 pandemic; effect of public health crises, including the current COVID-19 pandemic; Tonisity’s supply chain management; availability of suppliers of raw materials; limited or disrupted supply of key ingredients; the availability of key ingredients for Tonisity’s products; failure to expand production capacity; effect of product innovation; failure to retain current customers and/or recruit new customers potential volatility of share price; no assurance of active market for shares; dividends; global financial conditions; the effect of product labelling requirements; price of raw materials; consumer trends; publication of inaccurate or unfavourable research and reports; management and conflicts of interest.

Tonisity cautions that the foregoing list of material factors is not exhaustive. When relying on Tonisity’s forward-looking statements and information to make decisions, readers should carefully consider the foregoing factors and other uncertainties and potential events. Tonisity has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

The forward-looking information contained in this press release represents the expectations of Tonisity as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While Tonisity may elect to, it does not undertake to update this information at any particular time, except as required by applicable laws.

[1] N=398 piglets, *P=0.08.

[2] P=0.28 – 306 litters would be needed for the differences to be significant at P<0.05.

Other Useful Resources
Comparing the benefits of Tonisity Px to milk replacer for piglets in the first week of life
In order to give all the piglets in the litter equal chances of survival, cross-fostering and nursing sows are important...
3:1 Return on Investment with Tonisity Px
Analysis of the financial impact of using Tonisity Px on farms and the potential return of investment considering all cost...